REGENXBIO’s RGX-202 Shows 7.4 Improvement; Early Q2 2026 Data Expected
REGENXBIO’s RGX-202 DMD program reported a 7.4 mean functional improvement versus a CTAP model at 18 months and expects top-line pivotal data in early Q2 2026, with 12-month outcomes due by fall 2026 for majority of patients. The company holds $241 million cash, funding operations into early 2027.
1. DMD Program Highlights
RGX-202 Phase I/II data showed an average 7.4 improvement versus a CTAP model at 18 months, with consistent microdystrophin expression and no serious adverse events in patients aged eight or older. Management completed pivotal AFFINITY DUCHENNE dosing in October 2025 and plans top-line results in early Q2 2026, engaging the FDA mid-year on accelerated approval.
2. Financial Position
As of Q4 year-end 2025, the company holds $241 million in cash, sufficient to fund operations into early 2027, with potential extension into H2 2027 through milestone and royalty payments.
3. Ophthalmology Partnership
The AbbVie collaboration on RGX-314 advances with NAVIGATE DR first dosing expected next quarter, triggering a $100 million milestone, and wet AMD pivotal ATMOSPHERE and ASCENT readouts slated for Q4 2026 after Phase I/II trials reported a 93% reduction in annualized anti-VEGF injections.
4. MPS Program Regulatory Update
REGENXBIO received a CRL for RGX-121 and clinical holds on RGX-111/RGX-121 due to a vector genome integration event linked to tumor formation; the company is preparing a response and seeking a Type A meeting to address FDA concerns.